Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Beginner's Mind

Beginner's Mind artwork

EP 171 - Björn Cochlovius: Why Brilliant Biotech Breaks at Manufacturing

Feb 3, 20261 hr 6 minAudio

Most biotech breakthroughs don’t fail in the lab. They fail when science meets manufacturing reality. And by the time this bottleneck appears, tens of millions are already sunk. This episode examines the most under-discussed failure point in modern biotech: the gap between scientific discovery and scalable, usable healthcare solutions. While science has never been stronger - and big pharma excels at market access - companies that can translate breakthrough biology into industrialized medicines remain rare. Manufacturing, regulation, clinical design, usability for patients and physicians, and global scalability still form a narrow bottleneck where most value is lost. In this conversation, Björn Cochlovius, CEO of Eleva, explains why so many promising biologics fail late - and how Eleva deliberately built a platform designed not to replace existing systems, but to rescue projects that would otherwise be abandoned. Drawing on decades across immunology, biotech leadership, and translational medicine, Björn offers a grounded, operator-level view on what it actually takes to move from elegant science to real-world impact. As he puts it: (00:28:59) “In biotech, courageous decisions often look wrong - until years later.” This discussion goes beyond manufacturing alone. It explores why turning scientific concepts into ready-to-deploy healthcare solutions - complete with clinical data, regulatory pathways, scalable production, and high usability - remains one of the hardest industrial challenges of our time. What You’ll Learn in This Episode 1️⃣ Why biologics often fail late - after science already worked 2️⃣ Why manufacturing is only one part of a deeper industrial bottleneck 3️⃣ How Eleva approaches risk when others walk away 4️⃣ Why courage, not optimization, drives breakthrough biotech decisions 5️⃣ How AI supports discovery - without replacing human judgment 6️⃣ What Europe gets right - and still gets wrong - about scaling biotech 🧭 Selected Timestamps (00:03:00) Why biotech breakthroughs fail at manufacturing (00:07:18) Three takeaways for founders and investors short on time (00:08:36) Why biologics production breaks at scale (00:11:41) Salvaging proteins that standard systems cannot produce (00:15:27) The hidden opportunity in “failed” proteins (00:17:21) Why late-stage manufacturing failure destroys value (00:19:35) Why Eleva builds its own pipeline, not just a platform (00:22:46) Glycosylation as a source of better efficacy (00:27:03) Courageous decisions when everyone else has failed (00:30:04) Risk management through parallel scientific bets (00:32:08) Why similar proteins behave differently in patients (00:37:08) AI as a tool, not a replacement for human judgment (00:41:02) Why humans must remain accountable in drug discovery (00:44:25) The tension between basic research and development (00:46:01) Managing the handover between scientific universes (00:50:38) The CEO’s real job: building teams smarter than yourself (00:53:11) Leadership humility and protecting the team (00:56:11) How leaders recharge under long-term pressure (00:59:13) Europe’s biotech bottleneck and why there is still hope (01:02:20) Final reflection: turning science into systems that scale 🎙️ Beginner’s Mind Top 10% globally. Conversations for founders, investors, executives, and policymakers shaping the future of biotech, deep tech, and healthcare. Follow the show for more episodes where science meets strategy - and leadership determines what actually scales. Send us Fan Mail Support the show Join the Podcast Newsletter: Link Your Next Move: Link

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Spark 20: Alex Dang | Everyone Agrees? Think Again. How Venture Capitalists Decide

    Nov 1, 202629 minAudio

    Invest in the wrong startup and you lose one times your money. Miss the next Google and you lose ten thousand times. Most boards are built to avoid the first mistake. Venture capitalists play by different rules. They...

    Credit the people on this episode

  2. EP 185: Ivy Nguyen | IQ, EQ and the Execution Quotient Investors Fund

    Oct 18, 20261 hr 4 minAudio

    The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small...

    Credit the people on this episode

  3. EP 184: Ivy Nguyen | 10,000 AI Pitches and the One Test That Matters

    Oct 15, 202659 minAudio

    In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown...

    Credit the people on this episode

  4. EP 183: Marie Schroeder | Send the Rough Deck, Not the Perfect One

    Sep 27, 20262 hr 5 minAudio

    A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it...

    Credit the people on this episode

  5. #182 - How to Lead When You Don't Know Where You Are Going: 4 Lessons from Ben Horowitz (Part 2 of 2)

    Sep 8, 202657 minAudio

    What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to...

    Credit the people on this episode